ArticleApplied biochemistry and biotechnology2026
Semi-Rational Design of a Deep-Sea Metagenomic Sucrose Phosphorylase for Enhanced α-Arbutin Biosynthesis.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tilapia Skin-Derived Peptide PFRMY Attenuates Melanogenesis and Tyrosinase Activity via α-MSH/PKA/CREB Signaling Pathways in B16F10 Murine Melanoma Cells.Foods (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
α-Arbutin is widely recognized as a safe and highly effective skin-whitening agent in cosmetic formulations, owing to its superior tyrosinase inhibition compared to β-arbutin. In this study, a marine-derived sucrose phosphorylase (Suc75290) was engineered using a semi-rational design to enhance its efficiency in α-arbutin biosynthesis. Based on multiple sequence alignment and structural modeling, Arg134, situated within the flexible loop B near the active site, was identified as a crucial residue influencing hydroquinone (HQ) binding. Engineering of the Arg134 site, which had not been explored in previous sucrose phosphorylase studies for α-arbutin production, proved to be an effective strategy. Saturation mutagenesis of Arg134 identified the variant R134K, which exhibited the highest catalytic performance, showing a 62% increase in transglycosylation activity (9 U/mg) compared to the wild-type enzyme (5.6 U/mg). Under optimal bioconversion conditions (350 mM HQ, 1:6 HQ-to-sucrose molar ratio, 20 U/mL enzyme, pH 7.0–7.5, 45 °C, 36 h), an α-arbutin yield of 52 g/L was achieved. The improved activity and yield highlight the potential of the R134K mutant for the industrial-scale production of α-arbutin in cosmetic applications.
Indexed as
Identifiers
41504847What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.